<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44497">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527018</url>
  </required_header>
  <id_info>
    <org_study_id>2014-1232</org_study_id>
    <nct_id>NCT02527018</nct_id>
  </id_info>
  <brief_title>A Comparison of B Type Natriuretic Peptide Levels and Hemodynamics Using the Nexfin Device in Healthy Pregnant and Preeclamptic Women - A Pilot Study</brief_title>
  <official_title>A Comparison of B Type Natriuretic Peptide Levels and Hemodynamics Using the Nexfin Device in Healthy Pregnant and Preeclamptic Women - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertensive disorders of pregnancy including preeclampsia are the leading cause of
      pregnancy related mortality in the United States. Timely and appropriate management of
      hypertensive disorders of pregnancy is critical to prevent complications such as kidney
      failure, HELLP syndrome, disseminated intravascular coagulation, placental abruption,
      intrauterine fetal demise, intracranial bleed, coma and death. (HELLP syndrome is a group of
      symptoms that occur inpregnant women who have: H -- hemolysis (the breakdown of red blood
      cells); EL -- elevated liver enzymes; LP -- low platelet count.) Hypertensive disorders of
      pregnancy include gestational hypertension (HTN), chronic HTN, preeclampsia and preexisting
      HTN with superimposed preeclampsia.

      Hypertensive disorders may also lead to significant maternal and/or fetal morbidity. Based
      on the severity of the disease process and gestational age of the fetus, decision needs to
      be made whether to proceed with immediate delivery or continue expectant management.
      Meanwhile, maintenance of optimal blood pressure, blood volume, and cardiac output are
      recommended to preserve placental perfusion and to prevent unfavorable maternal and/or fetal
      outcomes.

      Previous studies have demonstrated blood flow differences in pregnancies complicated by
      preeclampsia vs. healthy pregnant women evidenced by decreased arterial compliance,
      increased systemic vascular resistance and after load, and changes in blood volume and
      cardiac output. Additionally, various serum markers have been tried to identify women with
      preeclampsia. B-Type natriuretic peptide (BNP) has been consistently shown to be elevated in
      preeclampsia, and serves as a marker of heart function and intra vascular volume status.

      Continuous hemodynamic monitoring may play a crucial role in timely management of these
      patients with severe disease due to the dynamic nature of the disease process. Existing
      methods are not preferred in pregnancy due to their invasive nature, and there is lack of
      validated non-invasive means to provide real time information on various hemodynamic
      parameters including cardiac output in these critically ill pregnant women.

      Among new cardiac monitoring devices, the Nexfin device (BMEYE, Amsterdam, Netherlands) has
      recently been introduced. Nexfin device is a device approved by the Food and Drug
      Administration (FDA) as a non-invasive reliable method of continuous measuring arterial
      blood pressure in pregnant women. However there are no preliminary data on preeclamptic
      patients using this device. The standard of care is to use a sphygmomanometer for blood
      pressure monitoring. Additionally there are no studies comparing the hemodynamics of healthy
      and preeclamptic women using Nexfin device. Nexfin is thought to be superior over other
      available non-invasive methods as it is a safe and a considerably accurate method. Nexfin
      provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic
      vascular resistance and left ventricular contractility indices.

      The study aims to determine if the non-invasive Nexfin device can be used to reliably
      distinguish hemodynamics in preeclamptic vs. healthy pregnant women with singleton
      pregnancies along with use of BNP levels. Investigators aim to recruit 33 healthy controls
      and 33 subjects diagnosed with preeclampsia (mild and severe). Subject's systolic and
      diastolic blood pressures will be measured using both the Nexfin device and a standard
      sphygmomanometer (blood pressure meter). Additionally hemodynamic measure such as: heart
      rate, cardiac output, stroke volume, systemic vascular resistance, and left ventricular
      contractility will be recorded using the Nexfin device. Investigators will perform a blood
      draw to measure BNP levels as an additional assessment of the hemodynamic changes in the two
      groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Endpoint: Quantify the hemodynamic changes in preeclampsia using the non-invasive
      Nexfin device.

      Secondary Endpoint: Determine if measurable hemodynamic changes are statistically correlated
      with B-type natriuretic peptide (BNP) levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Hemodynamic Preeclamptic Changes</measure>
    <time_frame>One hospital visit (duration 30 minutes).</time_frame>
    <description>Composite Changes are defined by volume overload (mL), higher B-type natriuretic peptide levels pg/mL, higher blood pressure or cardiac output (mm / Hg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Statistical Correlation For Normotensive and Preeclamptic Subjects</measure>
    <time_frame>One hospital visit (duration 30 minutes).</time_frame>
    <description>Composite Statistical Correlation are defined by systolic (SBP) and diastolic (DBP) levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Maternal</condition>
  <condition>Hypertension</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Measurement of hemodynamic levels (BNP) of healthly term subjects using the Nexfin sphygmomanometer device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preeclamptic Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Measurement of hemodynamic levels (BNP) of preeclamptic subjects using Nexfin sphygmomanometer device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sphygmomanometer</intervention_name>
    <description>Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>Preeclamptic Subjects</arm_group_label>
    <other_name>Nextfin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women aged (x&gt; or =18) with or without preeclampsia.

          -  Subjects with preeclampsia must have either mild or severe preeclampsia

          -  Healthy subjects should be normotensive

          -  Gestational age between 28 weeks to 40 0/7 weeks

        Exclusion Criteria:

          -  Pregnant women aged (x&lt;18)

          -  Pregnant women with multiple gestations

          -  Diagnosis of cardiac disease

          -  Diagnosis of vascular disease

          -  Diagnosis of end stage renal disease

          -  Subjects in active labor

          -  Diagnosis of Systemic Lupus Erythematosus or any other autoimmune disease

          -  Fetus' known to have age abnormality
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afshan Hameed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lili Sheibani, MD</last_name>
    <phone>(714) 456-6807</phone>
    <email>lsheibani@uci.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Department of OBGYN</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lili Sheibani, MD</last_name>
      <phone>714-456-6807</phone>
      <email>lsheibani@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Dmitry Portnoy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lili Sheibani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dezireh Khosravi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carol Major, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith Chung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deborah Wing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamera Hatfield, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julianne Toohey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shelly Dutt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deborah Karm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Briana Livingston, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacadi Bignami, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jamie Botelho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melinda Marshall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Duffy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chris LaFargue, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcie Rome, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Steller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Bonagura, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Revena Lukman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Neeper, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Sisto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth West, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Westermann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliet Wolford, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Cripe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Hodeib, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Johnston, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Lovell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allison Serra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Megan Stephenson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morgan Swank, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valeria Simon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cindy Chau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erica Wu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>August 17, 2015</lastchanged_date>
  <firstreceived_date>July 29, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Afshan B. Hameed, M.D.</investigator_full_name>
    <investigator_title>Associate Professor of Clinical OBGYN / Medical Director Obstetrical Services for OBGYN</investigator_title>
  </responsible_party>
  <keyword>OBGYN</keyword>
  <keyword>Nexfin</keyword>
  <keyword>Hypertensive</keyword>
  <keyword>Hemodynamic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
